Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02409901
Other study ID # 2011-0808
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date April 2025

Study information

Verified date June 2021
Source University of Illinois at Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized controlled trial (RCT) will examine the effect of a novel 12 month personalized exercise rehabilitation program compared to standard care following kidney transplantation. Return to work or find work rates, markers of subclinical atherosclerosis, functional capacity, body composition, quality of life, kidney function, and adherence to exercise will be measured. The investigators' primary hypothesis is that a 12 month exercise rehabilitation program will increase the return to work or find work rate in kidney transplant recipients. The investigators additionally hypothesize that a 12 month exercise rehabilitation program will prevent a decline in subclinical atherosclerosis, increase functional capacity, and increase lean muscle mass.


Description:

The proposed study, data collection, and intervention will be performed in the Integrative Physiology Laboratory at the University of Illinois at Chicago. Blood samples will be collected in the Transplant Clinic at the University of Illinois at Chicago. The study will use a two-arm RCT design to examine the effects of personalized exercise rehabilitation versus standard clinical care in kidney transplant (KT) recipients. The primary outcome will be patient return to work/find work rates. Secondary outcomes will include physical and vascular function, body composition, perceived quality of life, kidney function and blood lipid markers, and adherence. 120 kidney transplant recipients will be randomized 2:1 into either an exercise rehabilitation program or a control group, which involves standard clinical care only. Randomization will be done after obtaining informed consent and baseline testing, utilizing a computerized randomization program as a way to prevent potential selection bias. The exercise rehabilitation arm includes low intensity, personalized resistance trainings two times per week for a 12 month period in addition to standard clinical care (including regular check-ups and blood work as recommended by their post-transplant physician). The control group will continue standard care as advised by their post-transplant medical team with no additional intervention. The investigator will collect data on employment status, and all physiological and psychological data at baseline (before intervention), during (6 months), and immediately after the intervention (12 months). Adherence will be monitored throughout the entirety of the study by recording study visits as well as having the exercise trainers keep record of the patient's attendance in the exercise arm. A 2 X 3 (condition X time) mixed factor, analysis of variance with intent-to-treat principles will be utilized for testing the effect of the intervention on the outcome variables. The investigators' primary hypothesis is that a 12 month exercise rehabilitation program will increase the return to work/find work rate in kidney transplant recipients. It is additionally hypothesize that a 12 month exercise rehabilitation program will prevent a decline in subclinical atherosclerosis, increase functional capacity, and increase lean muscle mass. Outcome measures for subclinical atherosclerosis include aortic pulse wave velocity (PWV), carotid intima-media thickness (IMT), endothelial function and carotid arterial stiffness. The outcome measures for functional capacity include the 6 minute walk test (6MW), unilateral isometric strength test, and free-living accelerometry. Fat and lean muscle mass will be assessed via Dual-energy X-ray absorptiometry (DXA). Quality of life and perceptions of pain will be assessed utilizing the Patient Reported Outcomes Measurement Information System (PROMIS) Global health and PROMIS 29 v 2 questionnaires. Additionally, fasting blood lipid profile, inflammatory markers, and markers of kidney function including glomerular filtration rate (GFR) and creatinine levels will be measured.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 153
Est. completion date April 2025
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - at least 2 moths post-transplant - must have adequate cognitive ability to complete questionnaires, give consent for the study and follow the physical instructions Exclusion Criteria: - any other organ besides kidney or kidney/pancreas mix - any surgery or procedure to assist in weight loss (ie bariatric surgery) - non-ambulatory or significant orthopedic problems - cardiac/pulmonary disease that contraindicates the physical training - any contraindication to exercise testing per the American Heart Association - if the patient is unable to comply with the training program

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise Rehabilitation
12 month personalized exercise rehabilitation in addition to standard clinical care

Locations

Country Name City State
United States University of Illinois at Chicago Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Illinois at Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Return to work or find work rate This will be assessed through verbal questioning on current employment status 12 months
Secondary Subclinical atherosclerosis This will be assessed through measures of aortic pulse wave velocity (PWV) 12 months
Secondary Functional capacity This will be assessed through the 6 minute walk test (6MW) 12 months
Secondary Body Composition Fat and lean muscle mass will be assessed via Dual-energy X-ray absorptiometry (DXA). 12 months
Secondary Metabolic state and Kidney Function Fasting blood lipid profile will be measured 12 months
Secondary Quality of life and perceived health status The Patient Reported Outcomes Measurement Information System (PROMIS) v.1.1 - Global Health short form will be administered to all patients to assess perception of general health. 12 months
Secondary Subclinical atherosclerosis This will be assessed through measures of carotid intima-media thickness (IMT) 12 months
Secondary Subclinical atherosclerosis This will be assessed through measures of endothelial function and carotid arterial stiffness via flow mediated dilation (FMD). 12 months
Secondary Functional capacity This will be assessed through measures of unilateral isometric strength utilizing Biodex. 12 months
Secondary Regular physical activity This will be assessed through free-living accelerometry 12 months
Secondary Inflammatory marker C-reactive protein(CRP) 12 months
Secondary Metabolic state and Kidney Function Glomerular filtration rate (GFR) will be measured 12 months
Secondary Metabolic state and Kidney Function Creatinine levels will be measured. 12 months
Secondary Quality of life and perceived health status The PROMIS 29 Profile v2.0 will be administered to all patients to assess perception of general health. 12 months
Secondary Pro-inflammatory cytokines IL-6 will be measured. 12 month
Secondary Pro-inflammatory cytokines IL-1 will be measured. 12 month
Secondary Pro-inflammatory cytokines TNF-alpha will be measured. 12 month
Secondary Pro-inflammatory cytokines Homocysteine will be measured. 12 month
Secondary Pro-inflammatory cytokines Adiponectin will be measured. 12 month
Secondary Pro-inflammatory cytokines Leptin will be measured. 12 month
Secondary Pro-inflammatory cytokines Resistin will be measured 12 month
Secondary Pro-regenerative cytokines TGF-beta will be measured 12 month
Secondary Pro-regenerative cytokines IL-10 will be measured 12 month
See also
  Status Clinical Trial Phase
Completed NCT04087720 - Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant Phase 4
Completed NCT03749356 - Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients Phase 4
Withdrawn NCT05811468 - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT00498576 - Melatonin and Adiponectin in Hypertensive Kidney Transplant N/A
Completed NCT00642655 - Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation Phase 1/Phase 2
Completed NCT00374400 - The Paired Donation Consortium Paired Donation Program N/A
Completed NCT01710033 - A Study Of CP-690,550 In Stable Kidney Transplant Patients Phase 1
Completed NCT00205257 - Prediction of Acute Rejection in Renal Transplant Phase 1
Completed NCT02711826 - Treg Therapy in Subclinical Inflammation in Kidney Transplantation Phase 1/Phase 2
Withdrawn NCT03978494 - Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients. Phase 1
Completed NCT03837522 - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies N/A
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT05029310 - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients Phase 4
Completed NCT03644485 - Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients Phase 4
Completed NCT01047410 - ACtive Care After Transplantation, the ACT Study N/A
Completed NCT00940940 - Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Phase 4
Completed NCT00270712 - A Study of Factors That Affect Long-Term Kidney Transplant Function
Completed NCT00217126 - The Study of Long-term Deterioration of Kidney Transplants. Phase 4
Completed NCT00171496 - Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients Phase 4